Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Seattle Children's Hospital
Age
8–18
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Children and adolescents eight to eighteen years old
Diagnosis of inflammatory bowel disease (IBD) made by a pediatric gastroenterologist based upon history, physical examination, laboratory/radiological studies and gastrointestinal histology
Mild disease or in clinical remission based upon PUCAI or PCDAI score (score \<34 on the PUCAI or score \<30 on the PCDAI)
Parent/guardian and participant must be able to attend study visits at screening, baseline, and weeks three, six, and nine
Patient must be on a stable dose of IBD medications for at least 3 months
Patient must be able to swallow study medication
You may not be if
Abnormal laboratory values as defined in the protocol
History of increased gastrointestinal symptoms ("flare") in the last 3 months
Current use (past use of these medications is not an exclusion) of medications such as azathioprine, methotrexate or 6-mercaptopurine used to treat IBD
Current use (past use of these medications is not an exclusion) of medications or over-the-counter treatments including but not limited to aspirin, NSAID, botanical treatments (ginger, feverfew, yellow clover, Salix species, Populus species, Betula species, and Gaultheria species), essential fatty acids (flax oil and fish oil). Allowed supplementation includes multivitamin, vitamin D \& calcium, folate and vitamin B12, and Iron.
Other serious medical conditions such as neurological, liver, kidney, auto- immune or systemic disease.
History of gastrointestinal surgery or planned gastrointestinal surgery in the future.
Tobacco, alcohol, or illicit drug abuse
Planned surgery during the potential study participation time
